SARS-COV-2 infection in children and newborns: a systematic review

Ilaria Liguoro1, Chiara Pilotto2, Margherita Bonanni2

  • 1Department of Medicine DAME-Division of Pediatrics, University of Udine, P.zzale S. Maria della Misericordia, 15, 33100, Udine, Italy. ilarialiguoro@gmail.com.

Insights

Children infected with SARS-CoV-2, the virus causing COVID-19, generally experience milder symptoms than adults. This review highlights key clinical features and outcomes in pediatric cases, noting nonspecific lab and imaging results.

Area of Science:

  • Pediatric Infectious Diseases
  • Virology
  • Public Health

Background:

  • A novel Coronavirus, SARS-CoV-2, has caused a global pandemic.
  • Limited data exists on the clinical presentation and outcomes of SARS-CoV-2 in pediatric populations.

Purpose of the Study:

  • To systematically review the clinical characteristics and outcomes of SARS-CoV-2 infections in children.
  • To summarize the current understanding of COVID-19 in pediatric patients.

Main Methods:

  • Systematic review of studies published between January 1 and May 1, 2020.
  • Inclusion of papers reporting on children aged 0-18 years infected with SARS-CoV-2.
  • Analysis of data from 62 studies and 3 reviews, totaling 7480 children.

Main Results:

  • Most pediatric cases presented with mild (42.5%) or moderate (39.6%) symptoms.
  • Common symptoms included fever (51.6%) and cough (47.3%).
  • Mortality rate was low (0.08%), though newborns showed higher severe illness rates (12%).

Conclusions:

  • SARS-CoV-2 infection appears less severe in children compared to adults.
  • Laboratory and radiological findings are often nonspecific in pediatric COVID-19.
  • Further large-scale studies are needed to fully understand COVID-19 implications in children.

Related Concept Videos

Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
172
Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand  RNA genome. Its genome consists of four main open...
6.0K
Teratogenicity01:07

Teratogenicity

The ability of a drug to produce structural deformations and functional abnormalities in the developing embryo or the fetus is called teratogenicity, and the drug producing this effect is known as a teratogen. Teratogenic effects include stillbirth, miscarriage, intrauterine growth restriction, and neurocognitive delay. A teratogen may affect the embryo at different stages of development, which is important in determining the type and extent of the damage. During blastocyst formation, the early...
3.8K